Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4791-4797

  Breems, Dimitri A ^b   Van Putten, Wim L J ^b   De Greef, Georgine E ^b   Van Zelderen Bhola, Shama L ^b   Gerssen Schoorl, Klasien B J ^b   Mellink, Clemens H M ^b   Nieuwint, Aggie ^b   Jotterand, Martine ^b   Hagemeijer, Anne ^b   Beverloo, H Berna ^b   Löwenberg, Bob ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHROMOSOME; CHROMOSOME 7; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MONOSOMY 7; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 54349092877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.0259     Document Type: Article

References (14)

1. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
2. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived form the MRC AML 10 trial. Br J Haematol 107:69-79, 1999
3. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
4. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia group B (CALBG 8461). Blood 100:4325-4336, 2002
5. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
6. Mrózek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 169-177, 2006
7. Schoch C, Haferlach T, Haase D: Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: A study of 90 patients. Br J Haematol 112:118-126, 2001
8. Löwenberg B: Prognostic factors in acute myeloid leukemia. Best Pract Res Clin Haematol 14:65-75, 2001
9. Visani G, Bernasconi P, Boni M, et al: The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia: Analysis of 848 patients. Leukemia 15:903-909, 2001
10. Löwenberg B, Boogaerts MA, Daenen SMGJ, et al: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496-3506, 1997
11. Löwenberg B, Van Putten W, Theobald M, et al: Effect of priming with granulocyte-colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743-752, 2003
12. Breems DA, Boogaerts MA, Dekker AW, et al: Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128:59-65, 2005
13. Mitelman F (ed): ICSN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
14. Farag SS, Archer KJ, Mrozek K, et al: Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol 21:1041-1051, 2002